000916957 001__ 916957
000916957 005__ 20230929112504.0
000916957 0247_ $$2doi$$a10.1007/s11060-022-04218-x
000916957 0247_ $$2ISSN$$a0167-594x
000916957 0247_ $$2ISSN$$a0167-594X
000916957 0247_ $$2ISSN$$a1573-7373
000916957 0247_ $$2Handle$$a2128/34581
000916957 0247_ $$2pmid$$a36577872
000916957 0247_ $$2WOS$$aWOS:000905547600001
000916957 037__ $$aFZJ-2023-00223
000916957 082__ $$a610
000916957 1001_ $$0P:(DE-Juel1)190394$$aWollring, Michael M.$$b0$$eCorresponding author
000916957 245__ $$aClinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
000916957 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2023
000916957 3367_ $$2DRIVER$$aarticle
000916957 3367_ $$2DataCite$$aOutput Types/Journal article
000916957 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1687755480_30186
000916957 3367_ $$2BibTeX$$aARTICLE
000916957 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000916957 3367_ $$00$$2EndNote$$aJournal Article
000916957 520__ $$aPET imaging using radiolabeled amino acids in addition to MRI has become a valuable diagnostic tool in the clinical management of patients with brain tumors. This review provides a comprehensive overview of PET studies in glioma patients with a mutation in the isocitrate dehydrogenase gene (IDH). A considerable fraction of these tumors typically show no contrast enhancement on MRI, especially when classified as grade 2 according to the World Health Organization classification of Central Nervous System tumors. Major diagnostic challenges in this situation are differential diagnosis, target definition for diagnostic biopsies, delineation of glioma extent for treatment planning, differentiation of treatment-related changes from tumor progression, and the evaluation of response to alkylating agents. The main focus of this review is the role of amino acid PET in this setting. Furthermore, in light of clinical trials using IDH inhibitors targeting the mutated IDH enzyme for treating patients with IDH-mutant gliomas, we also aim to give an outlook on PET probes specifically targeting the IDH mutation, which appear potentially helpful for response assessment.
000916957 536__ $$0G:(DE-HGF)POF4-5253$$a5253 - Neuroimaging (POF4-525)$$cPOF4-525$$fPOF IV$$x0
000916957 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000916957 7001_ $$0P:(DE-HGF)0$$aWerner, Jan-Michael$$b1
000916957 7001_ $$0P:(DE-HGF)0$$aCeccon, Garry$$b2
000916957 7001_ $$0P:(DE-Juel1)145110$$aLohmann, Philipp$$b3
000916957 7001_ $$0P:(DE-Juel1)141877$$aFilss, Christian P.$$b4
000916957 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b5
000916957 7001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b6
000916957 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b7$$eCorresponding author
000916957 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-022-04218-x$$p481-488$$tJournal of neuro-oncology$$v162$$x0167-594x$$y2023
000916957 8564_ $$uhttps://juser.fz-juelich.de/record/916957/files/s11060-022-04218-x.pdf$$yOpenAccess
000916957 8767_ $$d2022-01-31$$eHybrid-OA$$jDEAL
000916957 909CO $$ooai:juser.fz-juelich.de:916957$$pdnbdelivery$$popenCost$$pVDB$$pdriver$$pOpenAPC_DEAL$$popen_access$$popenaire
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)190394$$aForschungszentrum Jülich$$b0$$kFZJ
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b3$$kFZJ
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)141877$$aForschungszentrum Jülich$$b4$$kFZJ
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b5$$kFZJ
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b6$$kFZJ
000916957 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b7$$kFZJ
000916957 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5253$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
000916957 9141_ $$y2023
000916957 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000916957 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000916957 915pc $$0PC:(DE-HGF)0002$$2APC$$aDFG OA Publikationskosten
000916957 915pc $$0PC:(DE-HGF)0113$$2APC$$aDEAL: Springer Nature 2020
000916957 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-08
000916957 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000916957 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-08
000916957 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2022-11-08$$wger
000916957 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000916957 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-20$$wger
000916957 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2022$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-20
000916957 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-20
000916957 920__ $$lyes
000916957 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000916957 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000916957 980__ $$ajournal
000916957 980__ $$aVDB
000916957 980__ $$aUNRESTRICTED
000916957 980__ $$aI:(DE-Juel1)INM-3-20090406
000916957 980__ $$aI:(DE-Juel1)INM-4-20090406
000916957 980__ $$aAPC
000916957 9801_ $$aAPC
000916957 9801_ $$aFullTexts